Presentation is loading. Please wait.

Presentation is loading. Please wait.

Phase I Clinical Study of the Angiogenesis Inhibitor TSU-68 Combined with Carboplatin and Paclitaxel in Chemotherapy-Naive Patients with Advanced Non-small.

Published byJohannes Arntzen Modified over 6 years ago

Similar presentations

Presentation on theme: "Phase I Clinical Study of the Angiogenesis Inhibitor TSU-68 Combined with Carboplatin and Paclitaxel in Chemotherapy-Naive Patients with Advanced Non-small."— Presentation transcript:

1 Phase I Clinical Study of the Angiogenesis Inhibitor TSU-68 Combined with Carboplatin and Paclitaxel in Chemotherapy-Naive Patients with Advanced Non-small Cell Lung Cancer  Isamu Okamoto, MD, PhD, Hiroshige Yoshioka, MD, Koji Takeda, MD, Miyako Satouchi, MD, PhD, Nobuyuki Yamamoto, MD, PhD, Takashi Seto, MD, Kazuo Kasahara, MD, PhD, Masaki Miyazaki, MD, PhD, Ryuichi Kitamura, PhD, Akio Ohyama, PhD, Noriko Hokoda, BS, Hiroshi Nakayama, MS, Eiji Yoshihara, MS, Kazuhiko Nakagawa, MD, PhD  Journal of Thoracic Oncology  Volume 7, Issue 2, Pages (February 2012) DOI: /JTO.0b013e d Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions

2 FIGURE 1 Patient disposition. ALT, alanine aminotransferase; AST, asparate aminotransferase. Journal of Thoracic Oncology 2012 7, DOI: ( /JTO.0b013e d) Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions

3 FIGURE 2 Time course of the plasma concentration of TSU-68 after administration of the first (day 1) or third (day 2) dose of the drug at 200 or 400 mg. Carboplatin and paclitaxel were coadministered on day 1. Data were presented as means ± SD. Journal of Thoracic Oncology 2012 7, DOI: ( /JTO.0b013e d) Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions

4 FIGURE 3 Changes in the plasma concentrations of biomarkers during treatment with TSU-68 in combination with carboplatin-paclitaxel chemotherapy. The plasma levels of VEGF-C and E-selectin were measured at baseline and after administration of three cycles of treatment for 19 patients. p values were determined with the paired exact Wilcoxon test (unadjusted). Journal of Thoracic Oncology 2012 7, DOI: ( /JTO.0b013e d) Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions

5 FIGURE 4 Tumor response. Maximal tumor shrinkage from baseline was determined for the 33 evaluable patients. Those showing a PR are indicated by asterisks. Journal of Thoracic Oncology 2012 7, DOI: ( /JTO.0b013e d) Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions

Download ppt "Phase I Clinical Study of the Angiogenesis Inhibitor TSU-68 Combined with Carboplatin and Paclitaxel in Chemotherapy-Naive Patients with Advanced Non-small."

Similar presentations

Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel, Carboplatin, and Bevacizumab in First-line Patients with Advanced Nonsquamous Non-small Cell.

Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel, Carboplatin, and Bevacizumab in First-line Patients with Advanced Nonsquamous Non-small Cell.
Circulating Endothelial Cells in Non-small Cell Lung Cancer Patients Treated with Carboplatin and Paclitaxel  Makoto Kawaishi, MD, Yutaka Fujiwara, MD,

Circulating Endothelial Cells in Non-small Cell Lung Cancer Patients Treated with Carboplatin and Paclitaxel  Makoto Kawaishi, MD, Yutaka Fujiwara, MD,
Su K. Metcalfe, MD, MPH, Michael T

Su K. Metcalfe, MD, MPH, Michael T
Elderly Patients with Advanced NSCLC in Phase III Clinical Trials: Are the Elderly Excluded from Practice-Changing Trials in Advanced NSCLC?  Adrian G.

Elderly Patients with Advanced NSCLC in Phase III Clinical Trials: Are the Elderly Excluded from Practice-Changing Trials in Advanced NSCLC?  Adrian G.
Tumor Response to Combination Celecoxib and Erlotinib Therapy in Non-small Cell Lung Cancer Is Associated with a Low Baseline Matrix Metalloproteinase-9.

Tumor Response to Combination Celecoxib and Erlotinib Therapy in Non-small Cell Lung Cancer Is Associated with a Low Baseline Matrix Metalloproteinase-9.
Phase II Study of Docetaxel and Carboplatin in Elderly Patients with Advanced Non- small Cell Lung Cancer  Naruo Yoshimura, MD, PhD, Shinzoh Kudoh, MD,

Phase II Study of Docetaxel and Carboplatin in Elderly Patients with Advanced Non- small Cell Lung Cancer  Naruo Yoshimura, MD, PhD, Shinzoh Kudoh, MD,
Outcomes of Second-Line Chemotherapy in Patients with Relapsed Extensive Small Cell Lung Cancer  Sandra Froeschl, MD, Garth Nicholas, MD, FRCPC, Victor.

Outcomes of Second-Line Chemotherapy in Patients with Relapsed Extensive Small Cell Lung Cancer  Sandra Froeschl, MD, Garth Nicholas, MD, FRCPC, Victor.
Phase II Trial of Weekly Dose-Dense Paclitaxel in Extensive-Stage Small Cell Lung Cancer: Cancer and Leukemia Group B Study 39901  Stephen L. Graziano,

Phase II Trial of Weekly Dose-Dense Paclitaxel in Extensive-Stage Small Cell Lung Cancer: Cancer and Leukemia Group B Study 39901  Stephen L. Graziano,
A Phase I Study of Pomalidomide (CC-4047) in Combination with Cisplatin and Etoposide in Patients with Extensive-Stage Small-Cell Lung Cancer  Peter M.

A Phase I Study of Pomalidomide (CC-4047) in Combination with Cisplatin and Etoposide in Patients with Extensive-Stage Small-Cell Lung Cancer  Peter M.
A Randomized, Double-Blind, Phase IIa Dose-Finding Study of Vandetanib (ZD6474) in Japanese Patients With Non-Small Cell Lung Cancer  Katsuyuki Kiura,

A Randomized, Double-Blind, Phase IIa Dose-Finding Study of Vandetanib (ZD6474) in Japanese Patients With Non-Small Cell Lung Cancer  Katsuyuki Kiura,
A Phase I Dose-Escalation Study of ZD6474 in Japanese Patients with Solid, Malignant Tumors  Tomohide Tamura, MD, Hironobu Minami, MD, Yasuhide Yamada,

A Phase I Dose-Escalation Study of ZD6474 in Japanese Patients with Solid, Malignant Tumors  Tomohide Tamura, MD, Hironobu Minami, MD, Yasuhide Yamada,
Large Cell Neuroendocrine Carcinoma of the Mediastinum with α-Fetoprotein Production  Ken Takezawa, MD, Isamu Okamoto, MD, PhD, Junya Fukuoka, MD, PhD,

Large Cell Neuroendocrine Carcinoma of the Mediastinum with α-Fetoprotein Production  Ken Takezawa, MD, Isamu Okamoto, MD, PhD, Junya Fukuoka, MD, PhD,
Rapid Response of Brain Metastasis to Crizotinib in a Patient with ALK Rearrangement– Positive Non–Small-Cell Lung Cancer  Hiroyasu Kaneda, MD, PhD, Isamu.

Rapid Response of Brain Metastasis to Crizotinib in a Patient with ALK Rearrangement– Positive Non–Small-Cell Lung Cancer  Hiroyasu Kaneda, MD, PhD, Isamu.
Efficacy and Safety of Erlotinib Monotherapy for Japanese Patients with Advanced Non- small Cell Lung Cancer: A Phase II Study  Kaoru Kubota, MD, PhD,

Efficacy and Safety of Erlotinib Monotherapy for Japanese Patients with Advanced Non- small Cell Lung Cancer: A Phase II Study  Kaoru Kubota, MD, PhD,
Asymptomatic Profound Sinus Bradycardia (Heart Rate ≤45) in Non-small Cell Lung Cancer Patients Treated with Crizotinib  Sai-Hong Ignatius Ou, MD, PhD,

Asymptomatic Profound Sinus Bradycardia (Heart Rate ≤45) in Non-small Cell Lung Cancer Patients Treated with Crizotinib  Sai-Hong Ignatius Ou, MD, PhD,
Association of the Expression of Mutant Epidermal Growth Factor Receptor Protein as Determined with Mutation-Specific Antibodies in Non-small Cell Lung.

Association of the Expression of Mutant Epidermal Growth Factor Receptor Protein as Determined with Mutation-Specific Antibodies in Non-small Cell Lung.
Ziad Thotathil, MD, FRCR, Jeremy Long, FRACP 

Ziad Thotathil, MD, FRCR, Jeremy Long, FRACP 
Elderly Patients with Advanced NSCLC in Phase III Clinical Trials: Are the Elderly Excluded from Practice-Changing Trials in Advanced NSCLC?  Adrian G.

Elderly Patients with Advanced NSCLC in Phase III Clinical Trials: Are the Elderly Excluded from Practice-Changing Trials in Advanced NSCLC?  Adrian G.
Successful Treatment with Erlotinib after Gefitinib-Induced Severe Interstitial Lung Disease  Masayuki Takeda, MD, PhD, Isamu Okamoto, MD, PhD, Chihiro.

Successful Treatment with Erlotinib after Gefitinib-Induced Severe Interstitial Lung Disease  Masayuki Takeda, MD, PhD, Isamu Okamoto, MD, PhD, Chihiro.
The Influence of the Evolution of First-Line Chemotherapy on Steadily Improving Survival in Advanced Non-Small-Cell Lung Cancer Clinical Trials  Krista.

The Influence of the Evolution of First-Line Chemotherapy on Steadily Improving Survival in Advanced Non-Small-Cell Lung Cancer Clinical Trials  Krista.

Similar presentations

Ads by Google